Company
Headquarters: Beijing, China
Employees: 531
CEO: Dr. Jisong Cui
HK$27.88 Billion
HKD as of July 1, 2025
US$3.55 Billion
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $309.91 B |
| Vertex Pharmaceuticals Incorporated | $117.36 B |
| CSL Limited | $95.75 B |
| Regeneron Pharmaceuticals, Inc. | $59.14 B |
| Marinomed Biotech AG | $58.56 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $699.59 B |
| Johnson & Johnson | $374.29 B |
| AbbVie | $336.94 B |
| Novo Nordisk | $309.91 B |
| UnitedHealth Group | $279.90 B |
InnoCare Pharma Limited, a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing drugs for the treatment of cancer and autoimmune diseases. It offers Orelabrutinib (ICP-022), a Bruton's tyrosine kinase for the treatment of chronic lymphocytic leukemia or small lymphocytic lymphoma, and relapsed and refractory mantle cell lymphoma. ICP-022 is in Phase II studies for patients with relapsed and refractory marginal zone lymphoma, relapsed and refractory central nervous system lymphoma, and relapsed and refractory Waldenstrom's macroglobulinemia; and in a Phase I clinical trial for follicular lymphoma patients, as well as Phase I basket trial for B-cell malignancies. The company is developing Gunagratinib( ICP-192), a pan-inhibitor of fibroblast growth factor receptor (FGFR) that is in Phase I/IIa clinical trial to define its maximum tolerated dose and/or optimal biological dose, and pharmacokinetics/ pharmacodynamics in patients with solid tumors; and ICP-105, a FGFR4 inhibitor, which is in Phase I dose escalation trial for the treatment of advanced hepatocellular carcinoma. It is also developing ICP-723, a pan-inhibitor of tropomyosin-related kinase family that is in Phase I clinical trial to treat patients with neurotrophic tyrosine receptor kinase fusion-positive cancers; and ICP-332, a small-molecule inhibitor of tyrosine kinase 2 for the treatment of various T-cell mediated autoimmune disorders, such as psoriasis, inflammatory bowel disease, and systemic lupus erythematosus. The company was incorporated in 2015 and is headquartered in Beijing, China.
| Last Financial Reports Date | June 30, 2024 |
| Revenue TTM | HK$1.34 B |
| EBITDA | HK$-365,658,468 |
| Gross Profit TTM | HK$1.18 B |
| Profit Margin | -22.88% |
| Operating Margin | -5.25% |
| Quarterly Revenue Growth | 129.90% |
InnoCare Pharma Ltd has the following listings and related stock indices.
Stock: HKEX: 9969 wb_incandescent